ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
AbbVie follows Gilead in throwing Xilio a lifeline.
The deal isn’t done, but would be Merck’s biggest oncology buy.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
